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Malignant melanoma is the most aggressive form of skin
cancer and has proven to be highly resistant to conven-
tional chemotherapy. Intriguingly, the p53 tumor suppres-
sor, a main mediator of chemoresistance in other tumor
types, is rarely mutated in melanoma. However, we have
previously shown that anti-apoptotic isoforms of p73 (TA-
p73), another member of the p53 family, are overexpressed
in metastatic melanomas. TA-p73 can oppose the pro-
apoptotic functions of p53 and full length p73, and thus
it could contribute to melanoma chemoresistance. In this
study, we use an efficient adenoviral-based gene transfer
approach to introduce a transcriptionally active form of p73
(TA-p73β) in melanoma cells, with the objective of over-
coming drug resistance. Interestingly, TA-p73β significantly
sensitized 5 out of 7 aggressive melanoma cell lines to
the standard therapeutic agents adriamycin and cisplatin.
More importantly, TA-p73β displayed a synergistic effect in
vivo allowing adriamycin or cisplatin to block melanoma cell
growth in mouse xenograft models (p < 0.05). In summary,
our data show that Ad-mediated TA-p73β gene expression
can markedly sensitize a subset of melanoma cell lines to
adriamycin and cisplatin in vitro and in vivo, suggesting a
new chemosensitization strategy for malignant melanomas.
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Introduction
Malignant melanoma has been one of the fastest rising ma-
lignancies in the last decades, with a life time risk currently
of 1/53. This highly aggressive form of skin cancer is cur-
able when resected at an early stage. In its metastatic stage,
melanoma has an extremely poor prognosis since chemother-
apy is ineffective due in part to the intrinsic and/or extrinsic
resistance of melanoma cells to systemic treatment with
anti-neoplastic agents.1 Most anticancer drugs kill suscep-
tible cells through the induction of apoptosis. Therefore
alterations of apoptotic pathways leading to apoptosis defi-
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ciency represent a potent mechanism conferring drug resis-
tance on melanoma cells.2 Acquired apoptotic defects during
melanoma progression involve activation of anti-apoptotic
factors, e.g. survivin,3 inactivation of proapoptotic factors,
e.g. Apaf-1,4 and upregulation of survival signals, e.g. B-
Raf.5 Restoration of the apoptotic pathway, e.g. by suppres-
sion of survivin3 or activation of Apaf-1,4 has been shown to
increase the sensitivity of melanoma cells to chemotherapeu-
tic agents. As an important molecular component of apopto-
sis p53 influences the resistance to chemotherapy in malig-
nant tumors. However, melanomas show a low frequency of
p53 mutations despite their extreme chemoresistance.6 One
explanation of this paradox is that disruption of pathways
upstream and/or downstream of p53 could functionally re-
place p53 loss during melanomagenesis, e.g. inactivation of
p14ARF7 or Apaf-1.4
The p53 family member p73 shares significant sequence
homology with p53. However, in contrast to p53, p73 gives
rise to multiple protein isoforms due to alternative pro-
moter utilization and alternative mRNA splicing.8 The TA
isoforms of p73, e.g. TA-p73α and TA-p73β, contain the
N-terminal transactivation domain. These TA-73 isoforms
can transactivate p53 target genes and induce apoptosis. In
addition, TA-p73 is induced by a wide variety of chemother-
apeutic drugs, such as adriamycin and cisplatin9–12 and
blocking of TA-p73 function has been shown to enhance
chemoresistance.11,13 Other p73 isofoms, namely TA-
73, lack the transcriptional activation domain and block
the pro-apoptotic function of p53 and TA-p73.14,15 Thus,
overexpression of TA-73 isoforms can block chemother-
apy induced apoptosis in tumor cells that retain wild-type
p53.15,16
Interestingly, a strong expression of p73 was found in
metastatic melanomas, suggesting that p73 might function
as a positive regulator of tumor growth in the progression
from primary melanoma to metastases.17 Detailed analyses of
p73 isoforms revealed an overexpression of TA-73 isoforms
in metastatic melanomas, suggesting a potential function of
TA-p73 in melanoma progression due to inhibition of p53
and TA-p73 function.18
These findings indicate that the ratio of TA-p73 to TA-
p73 may be an important determinant of drug response.
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Thus, we hypothesized that restoring TA-p73 function by
overexpression could confer sensitivity to chemotherapy-
induced apoptosis in tumor cells. Here we demonstrate that
upregulation of TA-p73β expression by adenoviral gene
transfer enhances chemosensitivity to adriamycin and cis-
platin in a subset of melanoma cell lines, both in vitro and
in vivo. Our data emphasizes the need of a comprehensive
analysis of p53 homologues in melanoma cells to understand
the molecular basis of drug resistance in this aggressive neo-
plasm.
Materials and methods
Cell lines and culture conditions
Human melanoma cell lines Mel1 (SK-Mel-19), Mel2
(SK-Mel-29), Mel3 (SK-Mel-103), Mel4 (SK-Mel-147),
Mel5 (G-361), Mel6 (UACC-257), all wild-type p53,
were derived from metastatic melanomas from patients.
Mel1-Mel6 were cultured in DMEM. DMEM was sup-
plemented with 10% heat-inactivated fetal bovine serum
(PAA Laboratories, Coelbe, Germany) and 100 units/ml
penicillin/streptomycin (GIBCO). Mel7 (WM115; gen-
erously provided by Dr. Birgit Schittek; Department
of Dermatology, Eberhard-Karls University, Tübingen,
Germany), wild-type p53, derived from primary melanoma,
was cultured in MCDB. MCDB was supplemented with
20% Leibowitz cell culture medium (L-15; GIBCO), 2.5%
heat-inactivated FBS, 100 mg/ml gentamycin (PAA), and
40 U/ml insulin (Aventis). Cells were cultured in a 5%
CO2 incubator at 37◦C. Medium was changed every
3 days.
Adenoviral vectors
Three replication-deficient recombinant adenoviral vectors,
Ad-GFP, Ad-GFP-TA-p73β, and Ad-TA-p73β, expressing
transgenes under the control of the CMV-promoter have
been described previously.19,20 All vectors were propagated
in 293 cells, purified by CsCl buoyant density centrifugation
and titrated by standard plaque assays.
Chemotherapeutic agents
For in vitro use adriamycin (ADR, doxorubicin; Pfizer) and
-cisplatin (cDDP, [cis-platinum(II)-diammine dichloride];
GRY) were diluted in culture medium before addition to
cell cultures. For in vivo use drugs were diluted in 100 µl
0.9% saline immediately before i.p. administration into
nude mice.
Adenovirus infection and drug treatment
1 × 106 melanoma cells were plated in 10-cm tissue culture
plates. After 24 h, cells were infected with adenoviral vector
at a multiplicity of infection (MOI 10 to 100) which allows
100% transduction of each cell line. For combination treat-
ment, chemotherapeutic agents were added to infected cells
at a concentration of 0.3 µg/ml for adriamycin and 3 µg/ml
for cisplatin. Cells were harvested 3 days after infection.
Real-time RT-PCR
Total RNA was isolated with the RNeasy Mini Kit
(Qiagen) according to the manfactures protocol and 1 µg
RNA was used for reverse transcription with Omniscript
RT (Qiagen) using random hexamers (Applied Biosystems).
PCR reactions contained 65 ng cDNA, 1 × Lithos qPCRTM
SYBR Green I Master Mix (Eurogentec), 150 nM of each
primer, 3.5 mM MgCl2 and 0.5 mg/ml BSA (Roche) and
were carried out in a LightCycler (RocheDiagnostics).
Amplification products for TA-p73, p73ex2, p73ex2/3,
N′-p73, N-p73, p21WAF1/CIP1 and S9 ribosomal
protein (S9ribP) were verified by melting curves, agarose
gel electrophoresis and direct sequencing. PCR conditions,
primer sequences and control plasmids were described
previously.14,18
Western blotting
Cells were lysed in RIPA buffer (50 mM Tris-Cl,
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS) and total protein concentration was quan-
titated by Bradford assay. Equal amounts of each sam-
ple were separated by SDS-PAGE, transferred to ni-
trocellulose membranes (Amersham-Biosciences; Freiburg,
Germany) and probed with antibodies against cleaved
Caspase-3 (#9661), full-length PARP (#9542), or cleaved
PARP (#9541) from Cell Signaling Technology (Frankfurt,
Germany). Reprobing of the blot with actin antibody
(Santa Cruz Biotechnology; #sc-1616, Heidelberg, Ger-
many) served as gel loading control. Primary antibod-
ies were detected with appropriate secondary antibody-
horseradish peroxidase conjugates (Amersham Pharmacia,
Braunschweig, Germany) according to the enhanced chemi-
luminescence protocol (Pierce).
Flow cytometry analysis
For flow cytometry analysis, adherent and nonadherent cells
were harvested, fixed in 70% (v/v) ethanol and stained for
DNA content with propidium iodide. FACS analysis was
performed at 3 days after infection. The data from 10,000
cells were collected and analyzed using CellQuestTM soft-
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ware (Becton Dickinson). The subdiploid population was
calculated as an estimate of the apoptotic cell population.
Analysis was carried out in a FACSCalibur flow cytome-
ter (Becton Dickinson, San Diego, USA) using CellQuest
Software.
Hoechst 33342 staining
At 3 days post infection Hoechst 33342 was added to the
cell culture medium at 1 µg/ml. Cells were incubated at
37◦C/5% CO2 and subsequently subjected to fluorescence
microscopy.
TUNEL assay
The immunohistochemic detection of apoptosis in formalin-
fixed, paraffin-embedded tumor tissues was performed by
using the Promega DeadEndTM Fluorometric TUNEL Sys-
tem. The TUNEL reaction mixture (50 µl) was applied to
deparaffinized and rehydrated tumor sections and the slides
were incubated for 60 min at 37◦C. The tissues were coun-
terstained with propidiumiodide and apoptotic cells were
determined by microscopic examination. For each tumor
three different slides were examined.
Animal experiments
Tumors were established by subcutaneous injection of
5 × 106 Mel3 or Mel4 cells into the right flank of athymic
BALB/c nu/nu mice (6–8 weeks of age). Mice with visi-
ble and palpable tumors received three direct intratumoral
injection of purified Ad-TA-p73β (5 × 109 pfu) or Ad-
GFP (5 × 109 pfu) every 3 days. Virus was diluted in
total volume of 100 µl of 0.9% saline and administered
in a single pass of a 27-gauge hypodermic needle using
constant infusion pressure. Beginning on day 7, mice were
treated with ADR (1 mg/kg), cDDP (6 mg/kg) or 0.9%
saline via i.p. injections every 3 days, for a total of five
treatments. Each experimental group consists of 6 mice.
The individual groups received the following treatment
combinations: group1, Ad-GFP+0.9% NaCl; group2, Ad-
GFP+ADR; group3, Ad-GFP+cDDP; group4, Ad-TA-
p73β+0.9% NaCl; group5, Ad-TA-p73β+ADR; group6,
Ad-TA-p73β+cDDP. Tumors were measured every 3 days
in two perpendicular diameters using calipers, and tumor
size was calculated using the formula: length (mm) × width
(mm2)/2. Animals were sacrificed when the longest diame-
ter was greater than 15 mm or when any two measurements
were greater than 10 mm. Animal experiments were per-
formed in accordance with institutional guidelines set by
the University Institutional Animal Care and Use Commit-
tee.
Statistical analysis
Statistic analysis was performed using paired two-sided Stu-
dent’s t test. P < 0.05 was considered as statistically signif-
icant.
Results
p73 expression status in melanoma cell lines
In order to determine which p73 isoforms are expressed in
the melanoma cell lines, total cellular RNA was purified
from cultured melanoma cells and transcript levels of TA-
p73 and TA-p73 (p73ex2, p732/3, N′-p73, N-
p73; Figure 1A) were quantified using real-time RT PCR.
As shown in Figure 1B, TA-p73 expression was observed
in all melanoma cell lines with highest transcript levels in
Mel7 and lowest transcript levels in Mel3. TA-p73 iso-
forms p73ex2, p732/3 and N-p73 were expressed in
all melanoma cell lines, except in Mel3 (p73ex2 and N-
p73 mRNA not detectable). In contrast, N′-p73 tran-
script expression was only detectable in 3/7 melanoma cell
lines (Mel2, Mel6, Mel7). Thus, all melanoma cell lines
significantly expressed both proapoptotic TA-p73 and anti-
apoptotic TA-p73 transcripts. An important issue to con-
sider is the ratio of the two antagonistic p73 protein classes.
5/7 melanoma cell lines showed an overweight of TA-p73
transcripts (TA-p73/TA-p73 ratios: Mel5, 6.9; Mel1, 5.4;
Mel4, 4.2; Mel7, 2.3; Mel2, 2.1), whereas 2/7 melanoma cell
lines revealed an overexpression of TA-p73 (TA-p73/TA-
p73 ratios: Mel3, 0.8; Mel 6, 0.4). On the protein level the
TA-p73/TA-p73 ratio might be higher, because the TA-
p73 proteins were reported to be more stable.19 However,
at present, it is not known how much TA-p73 activity
is required to outweigh the tumor suppressor function of
TA-p73. Taken together these data support a possible onco-
genic function of TA-p73 in the investigated melanoma
cell lines.
Induction of p21WAF1/Cip1 by TA-p73β
in melanoma cell lines
First, functional activity of the Ad-GFP-TA-p73β vector
was tested in melanoma cell lines by measuring expression
of p73 and its downstream target p21WAF1/Cip1. Cells were
infected either with Ad-GFP-TA-p73β or Ad-GFP, and
transcripts levels of TA-p73 and p21WAF1/Cip1 were quan-
tified at 36 h after infection using real-time RT PCR (Fig-
ure 2). As suggested, Ad-GFP-TA-p73β infected melanoma
cell lines showed increased TA-p73 expression in compari-
son to untreated controls with a fold induction ranging from
3.9 (Mel2) to 13.3 (Mel5), whereas upregulation of TA-p73
was not observed in Ad-GFP treated melanoma cells. In
all melanoma cell lines, p21WAF1/Cip1, known to be a p73-
dependent gene, was significantly transactivated following
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Figure 1. Expression of N-terminally truncated TP73 transcript isoforms in melanoma cell lines. (A) Schematic diagram of the various TA-
p73 isoforms. Exon structure of individual mRNAs, the promoter, from which they are transcribed, the encoded protein and their transactivation
function are as indicated. Red, transactivation domain; orange, exon 3B-derived coding sequence; blue, DNA-binding domain; grey, unique
5’ untranslated region of the N-p73 transcript. Primer localization is marked by arrows. (B) TP73 transcripts (TA-p73, p73ex2, p732/3,
N′-p73, N-p73) were quantified by real-time PCR. The bars show the absolute copy number normalized to S9 ribosomal protein (S9ribP)
transcript levels as a housekeeping gene. Errors bars indicate one SD. n.s. transcript expression not significant (P-values <0.05 were regarded
as statistically significant; paired, two-sided t-test).
Figure 2. Expression of TA-p73 (black bars) and p21 (gray bars) transcripts in melanoma cells 36 h after infection with Ad-GFP-TA-p73β
or Ad-GFP. Transcript copy numbers are calculated as fold inductions to untreated controls. Error bars indicate one SD of two independent
experiments. ∗, Significant differences (P < 0.05; paired, two sided t-test) between Ad-GFP and Ad-GFP-TA-p73β infected cells.
Ad-GFP-TA-p73β infection resulting in a 4.1- (Mel2) to
12.6-fold (Mel6) induction. In contrast, Ad-GFP infection
did not contribute to higher p21WAF1/Cip1 transcript levels.
Induction of apoptosis by TA-p73β
in melanoma cell lines
In order to examine whether apoptosis was induced by
the TA-p73β protein, melanoma cell lines were infected
either with Ad-GFP-TA-p73β or control virus (Figure 3).
The fate of infected GFP-positive melanoma cells was fol-
lowed by fluorescence microscopy. Unlike Ad-GFP infected
cells which had a normal morphology (Figure 3A), cell
overexpressing TA-p73β rounded up and showed typical
features of apoptotic cells characterized by membrane bleb-
bing, cell shrinkage, and intense staining of condensed chro-
matin as analyzed by Hoechst 33342 staining (Figure 3B).
As demonstrated in Figure 3C, increased expression of TA-
p73β in melanoma cells (shown for Mel4) was accompa-
nied by caspase-3 (Casp-3) activation and by cleavage of the
116 kD intact form of PARP to the 89 kD fragment which
is intimately linked to the induction of apoptosis. Both
Casp-3 and PARP cleavage became evident as early as 72 h
after infection. Flow cytometry analysis of cells infected with
Ad-GFP-TA-p73β revealed a sub-G1 population indicative
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Figure 3. Induction of apoptosis in melanoma cells by adenoviral TA-p73β transfer. Mel4 is shown as a representative cell line. (A) Cells
were stained with Hoechst 33342 at 72 h after infection and analyzed by laser scan microscopy. Infected cells are indicated as GFP positive.
(B) Higher magnification (x 20) of Ad-GFP-TA-p73ß infected cells showing typical features of apoptotic cells with membrane blebbing, cell
shrinkage, and nuclear condensation. (C) Caspase-3 activation and PARP cleavage analyzed by Western blotting using antibodies detecting
the 19 and 17 kD subunits of cleaved caspase-3 (Casp-3), full-length PARP and the 89 kD proteolytic cleavage product. Actin was used as a
loading control.
for apoptosis ranging from 7.7% (Mel6), 17.4% (Mel7),
20.6% (Mel4), 32.5% (Mel1), 36.6% (Mel2), 36.5% (Mel3)
to 42.1% (Mel5) at 3 days after infection (Figure 4), indi-
cating that the capability of TA-p73β to induce apoptosis
strongly differs between individual melanoma cell lines.
Sensitization of melanoma cell lines
to adriamycin and cisplatin by Ad-mediated
TA-p73β gene transfer in vitro
Recent reports showed that endogenous TA-p73 cooperates
with DNA-damaging agents to induce apoptosis in tumor
cells.9–12 Next, we investigated whether increased levels
of exogenous TA-p73β in melanoma cells could enhance
their sensitivity to chemotherapeutic drugs. Melanoma
cells infected with adenovirus vector (Ad-GFP-TA-p73β
or Ad-GFP) were subsequently treated with adriamycin or
cisplatin and harvested for cell cycle analysis. Ad-GFP-TA-
p73β infection resulted in a marked sensitization of several
melanoma cell lines to low concentrations of adriamycin
(ADR) and cisplatin (cDDP) as measured by flow cytometry
(see Figure 4A for an example of Mel4 and Figure 4B for
quantification analyses with all the cell lines in this study).
In lines 6 and 7, the effect of TA-p73β showed an addi-
tive effect with ADR or cDDP (Figure 4B). In Lines 1, 2
and 5, the impact of TA-p73β on drug response was syn-
ergistic with both drugs, and in lines 3 and 4 with ADR.
For example, compare the 12% or 18% killing by ADR
or cDDP single agents, respectively with a 80.6% in the
presence of overexpressed TA-p73β (-note that killing with
TA-p73β is limited to 32.5%; see Figure 4B). In contrast,
Ad-GFP infection had no obvious effect on drug sensitivity.
Taken together, these data indicate that adriamycin and/or
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Figure 4. Apoptotic effect of Ad-GFP-TA-p73ß and adriamycin or cisplatin combination treatment on human melanoma cells. Melanoma
cells were treated with Ad-GFP, Ad-GFP-TA-p73ß, adriamycin (ADR), cisplatin (cDDP) or combinations thereof as shown. Chemotherapeutic
agents were used at a concentration of 0.3 µg/ml for ADR and 3 µg/ml for cDDP. (A) Flow cytometry profiles showing DNA content (x-axis)
against cell number (y-axis). Mel4 is shown as a representative sample. The percentage of cells with a sub-G1 DNA content is as indicated.
(B) Flow cytometry results of two independent experiments ± SD (control light gray, Ad-GFP infected dark gray, Ad-GFP-TA-p73β infected
black). ∗ Significant differences (P < 0.05 paired, two sided t test) between Ad-GFP-TA-p73β and Ad-GFP infected cells or control cells.
cisplatin mediated cell killing can be efficiently enhanced
by TA-p73β gene expression in the majority of melanoma
cell lines. Apoptosis induction in response to Ad-GFP-TA-
p73β+ADR and Ad-GFP-TA-p73β+cDDP combination
therapies was also confirmed by Hoechst 33342 staining
(data not shown).
Antitumor effect of TA-p73β and ADR/cDDP
combination therapy in vivo
To determine the physiological impact of the results we
obtained in tissue culture systems, we analyzed the thera-
peutic efficacy of combination therapy on growing tumors
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Figure 5 (A) In vivo antitumor effect of TA-p73β/ADR or TA-p73β/cDDP combination therapy. After s.c. administration of 5×106 Mel3 or
Mel4 cells, palpable tumors were randomized to receive a local injection of Ad-GFP or Ad-TA-p73β on days 6, 9 and 12 followed by i.p.
injection of ADR (1 mg/kg) or cDDP (6 mg/kg) on days 7, 10, 13, 16, 19. The total virus dose was 3 × 5 × 109 pfu. Mice were monitored
for tumor regression over 21 days. The results are expressed as the mean from each treatment group ± SD. The differences in tumor size
in animals treated with Ad-TA-p73β+ADR or Ad-TA-p73β+cDDP were statistically significant compared with mice treated with Ad-TA-p73β
alone, Ad-GFP alone, Ad-GFP+ ADR or Ad-GFP+cDDP (day21, P < 0.05; paired two-sided t-test). The differences in tumor size in animals
treated with Ad-TA-p73β alone were statistically significant compared with mice treated with Ad-GFP alone, Ad-GFP+ADR or Ad-GFP+cDDP
(day21, P < 0.05; paired, two-sided t-test). (B) TUNEL staining for apoptotic cells in melanoma tissues (representative Mel3 tumors are shown)
at 72 h after intratumoral injection of 5 × 109 pfu Ad-GFP or Ad-TA-p73β. Increased apoptotis (green cells) was detected in Ad-TA-p73β
treated tumor tissue. A higher magnification (x 20) of apoptotic cells is shown in the right panel.
in mice. Established subcutaneous Mel3 and Mel4 tumors
were treated by three intratumoral injections of Ad-GFP or
Ad-TA-73β followed by five i.p. injections of either ADR or
cDDP over a period of 21 days and monitored for regression
(Figure 5A). Both Ad-GFP alone and in combination with
either drug showed a similar effect resulting in a pronounced
tumor growth. Compared to the controls, tumor growth was
markedly delayed after injection of Ad-TA-p73β (day 21,
P < 0.05; paired two-sided t-test). In both tumor models,
a significant reduction of tumor size was observed only af-
ter combination treatment of Ad-TA-p73β and adriamycin
or cisplatin (day 21, P < 0.05; paired two-sided t-test;
Figure 5), which resulted in a three week longer survival
of mice (data not shown). Importantly, no signs of systemic
toxicity were observed in animals receiving the combina-
tion therapy. These findings are in accordance to our in vitro
data, which demonstrated a synergistic effect of combined
Ad-TA-p73β/ADR treatment and an additive effect of Ad-
TA-p73β/cDDP combination therapy on cell death in Mel3
and Mel4 cells (Figure 4). Compared to Ad-GFP treated
controls, a positive TUNEL staining was detected only in
melanoma tissue injected with Ad-TA-p73β (Figure 5B),
indicating that apoptosis induction is the mechanism of
p73-mediated cytotoxicity in vivo.
Discussion
The success of systemic therapy for metastatic melanomas
has been minimal. Chemotherapeutic drugs could theoret-
ically target metastatic melanomas, but current treatments
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do not provide a significant therapeutic benefit.1 One of the
major mechanisms that contribute to chemotherapy medi-
ated tumor cell death is the induction of apoptosis. The
extreme resistance of malignant melanoma to chemothera-
peutic drugs, and the fact that apoptotic indices are typically
low in melanoma tumors, particularly at advanced stages,21
prompted an intense search for acquired apoptotic defects
during melanoma progression.2
p53 plays a central role in the apoptotic response to DNA
damaging agents. Consistent with its role in chemother-
apy induced apoptosis, p53 mutations have been linked
to chemoresistance in many types of cancer. Nonetheless,
melanomas display a low frequency of p53 mutations.6
One explanation for the extreme chemoresistance in the
presence of wild-type p53 in melanomas is that upstream
p53 regulators or downstream p53 mediators may func-
tionally replace p53 loss during melanomagenesis. For ex-
ample Apaf-1, which is an effective downstream mediator
of p53-induced apoptosis, is frequently downregulated in
metastatic cell lines and tumor specimens22–24 and restora-
tion of Apaf-1 function through gene transfer has been
shown to enhance chemosensitivity.4 However, other mech-
anisms should contribute to the malignant phenotype of
melanoam cells since Apaf-1 overexpression does not com-
pletely restore drug response.25 We had previously shown
that metastatic melanoma cells have a dysregulated expres-
sion of different isoforms of p73, a factor that shares tumor
suppressor functions with p53. Here we show that melanoma
cells express a higher ratio of anti- to pro-apoptotic iso-
forms of p73. Reverting this ratio by overexpression of full-
length p73 significantly sensitized melanoma cells to the the
chemotherapeutic drugs adriamycin and cisplatin (otherwise
poorly effective in melanoma).
It has been puzzling that p73, to the contrary to p53,
can be upregulated in human tumors. In some cases,
overexpression of p73 could even be correlated with an
advanced tumor stage or poor prognostic parameters.26,27
Moreover, various chemotherapeutic drugs, such as adri-
amycin and cisplatin, mediate apoptosis in cancer cells in
part by upregulating p73 transcripts and stabilizating p73
protein via c-Abl.9–12 However, the fact that anti-apoptotic
isoforms can also be upregulated in tumor cells,8,14,15
emphasizes the complexity of p73 function. The TA-p73
proteins can be generated by the following two mechanisms:
(a) abberant splicing (p73ex2, p73ex2/3, N′-p73)
and (b) alternative usage of a second intrinsic promoter
(N-p73).8 TA-p73 proteins were shown to compromise
p53- and TA-p73-dependent apoptosis16,19 and thereby to
promote malignant transformation.15,28
Malignant melanomas have also been shown to express
high levels of wild-type p73,17,29 but also TA-p73 levels
(mostly TA-promoter derived p73ex2/3 and p73ex2
isoforms).18 Thus, TA-p73 upregulation is another
possible mechanism that may functionally replace p53
loss during melanomagenesis. Here we further extend
this previous data, showing that transactivation-deficient,
anti-apoptotic TA-p73 isoforms are expressed in 7/7
of our melanoma cell lines, suggesting a possible role of
TA-p73 in apoptosis-deficiency and chemoresistance by
inhibition of p53 and TA-p73 function.
Thus, we hypothesized that a therapeutic approach for
sensitizing melanoma cells to chemotherapeutic drugs
could be antagonizing TA-p73 function and restoring
p73-mediated apoptosis by overexpression of TA-p73. In
melanoma cell lines both p53 and TA-p73β gene transfer
has been reported to promote apoptosis.30,31 Here we
show that TA-p73β is more effective as a chemosensitizing
factor. When TA-p73β was combined with adriamycin
we observed a synergistic effect on apoptotic cell death
in 5/7 melanoma cell lines in vitro. As a potential reason
of why these five cell lines, and not the other two, are
sensitive to TA-p73β one could expect differences in the
ratio of TA:TA isoforms. However, there was no signif-
icant correlation between the lack of TA-p73β-mediated
chemosensitivity and the ratio of anti-apoptotic versus
apoptotic p73 in these cell lines. We can thus speculate that
other factors such as a variable induction of p73 downstream
target genes or the failure of some cells to express the trans-
duced gene even after 100% infection explain the difference
in therapeutic outcome. Both, adriamycin and cisplatin also
cooperated with TA-p73β to enhance antitumor activity in
xenograft tumors using Mel3 and Mel4 cells. Most impor-
tantly, the significant drug-sensitizing effect of TA-p73β
found in vivo, supports the development of novel therapeutic
strategies aiming to block TA-p73 or to exploit the
TA-p73β levels that melanoma cells intrinsically express.
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